期刊文献+

盐酸多奈哌齐治疗血管性痴呆的临床疗效观察 被引量:21

The Clinical Observation of Efficiency of Donepezil in Treatment of Vascular Dementia
下载PDF
导出
摘要 目的观察盐酸多奈哌齐治疗血管性痴呆的疗效。方法102例血管性痴呆患者随机分为2组,治疗组51例,在常规治疗的基础上给予盐酸多奈哌齐5mg,每日1次;对照组54例,给予常规治疗,两组患者疗程均为12周,观察治疗前后认知功能(MMSE、HDS)及日常生活自理能力(ADL)的改善程度。结果治疗12周时,治疗组MMSE、HDS及ADL评分明显改善,较对照组有显著性差异(P<0.05),自身对照结果显示,盐酸多奈哌齐治疗12周,治疗后MMSE、HDS及ADL评分较治疗前改善(P<0.01),在治疗4周时,MMSE、HDS及ADL评分已有提高。结论盐酸多奈哌齐治疗血管性痴呆疗效确切,对患者认知功能及日常生活能力均为改善,无明显副作用,值得临床推广。 Objective To evaluate the efficiency of donepezil for vascular dementia(VaD). Methods 105 cases of patients with VaD were randomly divided into 2 groups;the treated group(51 cases) and the control group(54 cases),patients in treated group were given donepezil (Smg,once daily) in the foundation of conventional therapy;and other group was treated by conventional therapy,taking 12 weeks clinical therapy,To observate the degree of improvement for the cognitive function(MMSE,HDS) and the ability of taking care of oneself(ADL). Results After 12 weeks,the marks of MMSE,HDS and ADL of the treatment group were more evidently improved than that of the control group(P〈0.05),the study indicated that the marks of MMSE,HDS,ADL compare to the comparison group improved in turn after treatment(P〈0.01),after having been treated for 4 weeks,the marks of MMSE,HDS and ADL have been improved(P〈0.05). Conclusion Donepezil which can improve the cognitive function and the ability of taking care of oneself,is effective for VaD and no side effect, worthing spreading in clinic.
出处 《中国老年保健医学》 2008年第4期31-33,共3页 Chinese Journal of Geriatric Care
关键词 盐酸多奈哌齐 血管性痴呆 临床疗效 donepezil,vascular dementia, clinical efficiency
  • 相关文献

参考文献3

二级参考文献30

  • 1Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon 4 allele, elevated midlffe total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzhekner disease. Ann Intern Med, 2002. 137:149 - 155.
  • 2Meyer JS, Rauch G, Rauch RA, et al. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Nenrobiol Aging, 2000, 21 : 161 - 169.
  • 3Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet, 1996, 347:1141 - 1145.
  • 4Petrovitch H, White LR, Izmirilian G, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brah weight at death: the HAAS. Honokdu-Asia aging Study. Neurobiol Aging, 2000, 21:57 -62.
  • 5de la Torre JC. Cerebral hypoperfusion, capiliary degeneration, and development of Alzhehner disease. Alzheimer Dis Assoc Disord, 2000,14(Suppl 1): S72 -S81.
  • 6Swan GE, DeCarli C, Miller BL, et al. Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology, 1998, 51:986 -993.
  • 7DeCarli C, Murphy DG, Tranh M, et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose m 51 healthy adults. Neurology, 1995,45: 2077 - 2084.
  • 8Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 1993, 261:921 -923.
  • 9Zarow C, Zaias B, Lyness SA, et al. Cerebral amyioid angiopathy Alzhehner disease is associated with apolipoprotein E4 and cortical neuron loss. Alzheimer Dis Assoc Disord, 1999, 13:1 -8.
  • 10Kosunen O, Talasniemi S, Lehtovirta M, et al. Relation of coronary atherosclerosis and apolipoprotein E genotypes in Alzheimer patients.Stroke, 1995, 26:743 -748.

共引文献91

同被引文献106

引证文献21

二级引证文献182

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部